Methodology: 4/5
Usefulness: 4/5

de-Madaria E, et al. N Engl J Med. 2022 Sep 15;387(11):989-1000.

Question and Methods: A multicenter, open-label, randomized control trial assessing the use of aggressive versus moderate fluid resuscitation in acute pancreatitis and the development of moderate severe or severe pancreatitis and fluid overload. 
Findings:  The trial stopped early given significant difference in development of fluid overload (20.5% in aggressive-resuscitation group versus 6.3% in moderate-resuscitation group; adjusted relative risk, 2.85; 95% CI, 1.36 – 5.94, P=0.004) without any significant difference in incidence of moderately severe/severe pancreatitis (22.1% in the aggressive-resuscitation group versus 17.3% in the moderate-resuscitation group; adjusted relative risk,1.30; 95% CI, 0.78 – 2.18; P=0.32).  
Limitations: Given eligibility criteria, trial population may have had less severe disease. Open-label trial with subjective assessments of fluid status. Moderate-resuscitation group only received a bolus if they were hypovolemic, while aggressive-resuscitation group received an initial fluid bolus whether hypovolemic or not, possibly contributing to fluid overload. 

Interpretation: In acute pancreatitis, aggressive fluid resuscitation should be avoided. Further, patients with normovolemia should not receive fluid boluses. Both of these may lead to fluid overload, which can be harmful for the patient.  

By: Dr. Kate Holden-Boyd

Supervisor: Dr. Krishan Yadav




  • Kate Holden-Boyd

    Dr. Kate Holden-Boyd CCFP, MBChB

    View all posts
  • Hans Rosenberg

    Dr. Rosenberg is an emergency physician at the Ottawa Hospital, associate professor at the University of Ottawa, and Director of the Digital Scholarship and Knowledge Dissemination Program.

    View all posts
  • Krishan Yadav

    Dr. Krishan Yadav is an FRCPC Emergency Medicine Physician, and Epidemiologist with a special interest in non-purulent skin and soft tissue infectious disease.

    View all posts